Literature DB >> 23025970

Factors associated with prophylactic plasma transfusion before vascular catheterization in non-bleeding critically ill adults with prolonged prothrombin time: a case-control study.

D P Hall1, N I Lone, D M Watson, S J Stanworth, T S Walsh.   

Abstract

BACKGROUND: Fresh-frozen plasma (FFP) is widely used in critically ill patients, despite a weak evidence base. Factors that influence the decision to transfuse FFP before intravascular catheter insertion are poorly described.
METHODS: We undertook a case-controlled study based on a prospective cohort study of 1923 admissions to 29 intensive care units in the UK. Non-bleeding patients with an international normalized ratio (INR) ≥1.5 who underwent intravascular catheterization, but no other invasive procedure, were identified. We compared patient characteristics, illness-related factors, and biochemical and haematological variables between patients who did or did not receive pre-procedural FFP.
RESULTS: One hundred and eighty-six patients fulfilled the criteria; 26 received FFP during the 24 h before line insertion (cases) and 160 did not (controls). Factors associated with greater use of prophylactic FFP by clinicians were pre-existing chronic liver disease (P=0.01), higher serum bilirubin before procedure (P=0.01), lower platelet count (P=0.01), higher activated partial thromboplastin time (P=0.001), lower fibrinogen (P=0.01), and concurrent red cell transfusion despite the absence of bleeding (P=0.001). There was no difference in pre-procedural INR [median (1st, 3rd quartile) cases: 1.95 (1.85, 2.6); controls 1.8 (1.6, 2.3); P=0.19]. The mean FFP dose was 11.1 ml kg(-1) (sd 5.7 ml kg(-1)); 53.8% of cases were transfused <10 ml kg(-1).
CONCLUSIONS: Chronic liver disease and more abnormal coagulation tests were associated with greater probability of pre-procedural FFP administration before vascular catheterization, whereas the severity of prothrombin time prolongation alone was not. FFP was more likely to be administered when red cells were also transfused, even in the absence of bleeding.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23025970     DOI: 10.1093/bja/aes337

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  7 in total

1.  Identification of Clinically Meaningful Plasma Transfusion Subgroups Using Unsupervised Random Forest Clustering.

Authors:  Che Ngufor; Matthew A Warner; Dennis H Murphree; Hongfang Liu; Rickey Carter; Curtis B Storlie; Daryl J Kor
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

2.  Plasma transfusions prior to insertion of central lines for patients with abnormal coagulation.

Authors:  David P Hall; Lise J Estcourt; Carolyn Doree; Sally Hopewell; Marialena Trivella; Timothy S Walsh
Journal:  Cochrane Database Syst Rev       Date:  2015-06-20

3.  Peri-procedural management of bleeding risks in critical care patients: A local audit and national survey.

Authors:  Stephen P Hibbs; Stuart McKechnie; Mark Little; Raman Uberoi; Michael J Desborough
Journal:  J Intensive Care Soc       Date:  2014-12-09

Review 4.  Risk of Procedural Hemorrhage.

Authors:  Krysta S Wolfe; John P Kress
Journal:  Chest       Date:  2016-02-02       Impact factor: 9.410

Review 5.  Plasma transfusions prior to insertion of central lines for people with abnormal coagulation.

Authors:  David P Hall; Lise J Estcourt; Carolyn Doree; Sally Hopewell; Marialena Trivella; Timothy S Walsh
Journal:  Cochrane Database Syst Rev       Date:  2016-09-20

6.  Predictors of unattempted central venous catheterization in septic patients eligible for early goal-directed therapy.

Authors:  David R Vinson; Dustin W Ballard; Matthew D Stevenson; Dustin G Mark; Mary E Reed; Adina S Rauchwerger; Uli K Chettipally; Steven R Offerman
Journal:  West J Emerg Med       Date:  2014-02

7.  Adding up the evidence: Trigger for prophylactic plasma transfusion.

Authors:  Manish Raturi; Shamee Shastry; Poornima B Baliga
Journal:  Asian J Transfus Sci       Date:  2017 Jul-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.